Market Currents
The FDA extends its review date for the MS drug Tysabri - produced by Biogen Idec (BIIB) and...
-
Friday, October 21, 2011, 8:18 AM ETThe FDA extends its review date for the MS drug Tysabri - produced by Biogen Idec (BIIB) and Elan (ELN) - indicating it needs the extension to review changes in the risk evaluation and mitigation strategies for the drug. Premarket: BIIB -6%, ELN inactive.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
